PATENT CLAIM ANALYSIS

Application Number: 16361370
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["424", "577000"]

Abstract:
A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

Claim (Index 45):
The combination therapy of  claim 41 , wherein the engineered T-cell expresses a CAR, a multi-chain CAR or a pTalpha transgene.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 99.0
- Lexical Diversity: 1.5375
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15659792', '14403937', '15711289', '14018021', '15302450']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8619090233066368
- 35 USC 102 Novelty (BERT): 0.6277022612089254
- Combined Prediction Score: 0.8384883470968657
- Mean Citation Score: 732.800604
- Max Citation Score: 843.6123
- Similarity Product: 512.470802936697

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test